Our goal is to realize the potential of cancer immunotherapy by extending the anti-cancer activity of CAR T-cell therapy to solid tumors. AffyImmune’s proprietary technology enhances the ability of a patient’s own immune cells to attack and destroy solid tumors, while avoiding damage to normal cells and tissues.


Our core focus is on fine-tuning the affinity of CAR T cells to selectively kill tumor cells, while sparing healthy cells to prevent toxicity and ensuring more natural, robust and long lasting activity of the CAR T cells. We engineer our CAR T cells to enable their distribution and activity to be monitored in real-time in patients during treatment.
Discover More


Our leadership team combines a depth of experience in biotechnology drug development with a passion for creating new, patient-centric, life-saving treatments.
Get to Know Us


Track our progress as we develop affinity-tuned CAR T-cell therapies to treat solid tumors.
View Pipeline